Trastuzumab
[CAS# 180288-69-1]

Identification

• Classification: API >> Antineoplastic agents >> Natural source antineoplastic agents
• Name: Trastuzumab
• Synonyms: Herceptin
• Protein Sequence: Anti-HER2 Light chain (1 and 2); DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS; RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP; SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT; LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; ; Anti-HER2 Heavy chain (1 and 2); EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY; ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS; ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS; GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG; PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN; STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE; MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW; QQGNVFSCSVMHEALHNHYTQKSLSLSPGK
• Molecular Formula: C₆₄₇₀H₁₀₀₁₂N₁₇₂₆O₂₀₁₃S₄₂
• Molecular Weight: 145529.81
• CAS Registry Number: 180288-69-1
• EC Number: 695-702-2

Properties

• Melting point: 61 ºC, 71 ºC

Safety Data

• Hazard Symbols: GHS08 Danger
• Hazard Statements: H360
• Precautionary Statements: P203-P280-P318-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Reproductive toxicity	Repr.	1A	H360

Discovory and Applicatios

Trastuzumab, also known as Herceptin, was developed in the late 20th century by researchers Genentech, a biotechnology company. The discovery of trastuzumab stemmed from the identification of the HER2/neu (Human Epidermal Growth Factor Receptor 2) gene, which is overexpressed in certain types of breast cancer. Trastuzumab was specifically designed as a monoclonal antibody to target and inhibit the HER2 protein.

Trastuzumab revolutionized the treatment of HER2-positive breast cancer, significantly improving survival rates and outcomes for patients. It is used in both early-stage and metastatic HER2-positive breast cancer, often in combination with chemotherapy or other targeted therapies. Trastuzumab has also shown efficacy in HER2-positive gastric cancer, expanding its therapeutic applications beyond breast cancer.